Seeking Alpha

Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good...

Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed or refractory lymphoma in a Phase I trial. Pacritinib has already performed well in Phase II studies for patients with myelofibrosis, and the company intends to carry out Phase III trials for this bone-marrow illness. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|